Navigation Links
Neurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference
Date:9/10/2015

SAN DIEGO, Sept. 10, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, resident and CEO of Neurocrine Biosciences, will be presenting at the Morgan Stanley Global Healthcare Conference in New York City.

The live presentation takes place on Thursday, September 17 at 8:00am ET (5:00am PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.  

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and NBI-98854, a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.  Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. 

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

 


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference
2. Neurocrine Biosciences to Present at the Jefferies 2013 Global Healthcare Conference
3. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
4. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
5. Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
6. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
7. Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results
8. Neurocrine Biosciences To Present At Oppenheimers 24th Annual Healthcare Conference
9. Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study
10. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
11. Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2019)... ... December 06, 2019 , ... ... implementation this month, Kenall is introducing the CSEDOIC luminaire series. CSEDOIC fixtures are ... now requires the unpacking of hazardous drugs (HDs) and HD-active pharmaceutical ingredients from ...
(Date:12/6/2019)... ... December 06, 2019 , ... ... announce an expansion in services. While Kindred Nutrition and Wellness will continue ... they are now happy to offer Individual and Family Therapy and Yoga. , ...
(Date:12/6/2019)... ... December 06, 2019 , ... The Multiple System Atrophy Coalition ... bold new initiative to kickstart MSA research collaborations. Multiple system atrophy is ... by $3 million in new bequests earmarked for research and combined with ongoing ...
Breaking Medicine Technology:
(Date:12/8/2019)... ... , ... Intelligent.com, a trusted resource for online degree rankings ... 2020. The comprehensive research guide is based on an assessment of 104 accredited ... quality, graduation rate, reputation, and post-graduate employment. , The 2020 rankings are ...
(Date:12/6/2019)... Conn. (PRWEB) , ... December 06, 2019 , ... ... is consistently recognized for its innovations and excellence in patient care. On December ... that standard of excellence at the Health Care Heroes Awards at the Hartford ...
(Date:12/6/2019)... ... 06, 2019 , ... COMPLIANCY GROUP is proud to announce ... Society. Compliancy Group is dedicated to educating and assisting Wyoming Medical Society’s members ... the standards set forth by the Health Insurance Portability and Accountability Act (HIPAA). ...
(Date:12/5/2019)... ... December 05, 2019 , ... A cohort of plastic ... to help their patients more easily detect ruptured silicone gel implants. Dr. Herluf ... and reporting on his experience. While the FDA currently recommends regular MRI scans ...
(Date:12/5/2019)... ... 05, 2019 , ... It’s been an impactful year for ... people embrace, achieve, and maintain a healthy lifestyle to giving generously to communities ... mission of impacting world health, so it’s gratifying to look back on the ...
Breaking Medicine News(10 mins):